Discriminant Accuracy of the SOFA Score for Determining the Probable Mortality of Patients With COVID-19 Pneumonia Requiring Mechanical Ventilation | Critical Care Medicine | JAMA jamanetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jamanetwork.com Daily Mail and Mail on Sunday newspapers.
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET | Source: BioAegis Therapeutics BioAegis Therapeutics Morristown, New Jersey, UNITED STATES
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announced today that studies from three independent groups of investigators, including the NIH, have reported
that low levels of gelsolin are associated with severity and organ failure in COVID-19 patients, with the lowest pGSN levels seen in patients who subsequently died. BioAegis is currently conducting a Phase 2 clinical trial of recombinant human plasma gelsolin (rhu-pGSN) in severe COVID-19 patients to supplement gels
January 13, 2021
Another randomized trial, REPLACE COVID, indicates that patients already taking ACE inhibitors and ARBs when they’re hospitalized for COVID-19 should continue to do so, supporting recommendations from international CV societies.
When it came to outcomes including all-cause death, duration of mechanical ventilation, time on renal replacement or vasopressor therapy, and multiorgan dysfunction during hospitalization, there were no differences between patients who continued versus discontinued their renin-angiotensin-aldosterone-system (RAAS) inhibitors after they were admitted, researchers report in a study published online last week in the
Lancet Respiratory Medicine.
More of TCTMD s coverage on our COVID-19 hub.
Considering these findings and those from the BRACE CORONA trial, presented last year at the virtual European Society of Cardiology Congress, the message is simple, according to senior author Julio Chirinos, MD, PhD (University of Pennsylvania, Philade
FAIRFIELD-SUISUN, CALIFORNIA
‘Triage officers’ would decide who gets care and who doesn’t if COVID-19 cripples LA County hospitals [Los Angeles Times :: BC-CORONAVIRUS-LA-TRIAGE:LA]
LOS ANGELES – Stretched to the breaking point by a deluge of COVID-19 patients, Los Angeles County’s four public hospitals are preparing to take the extraordinary step of rationing care, with a team of “triage officers” set to decide which patients can benefit from continued treatment and which are beyond saving and should be allowed to die.
The county’s top health officials have not yet declared a shift to a crisis level of care, which would trigger the rationing system, but the leader of the public hospitals acknowledged in a letter reviewed by The Times this week that “there will likely come a point when we simply don’t have sufficient staffing or critical supplies to care for all our patients in the way we normally would.”
FAIRFIELD-SUISUN, CALIFORNIA
TORRENCE, CA - DECEMBER 29: Hospital doctors and nurses work treating COVID-19 patients in a makeshift ICU wing on the West Oeste at Harbor UCLA Medical Center on Tuesday, Dec. 29, 2020 in Torrence, CA. The hospital has no open beds for incoming patients and have worked tirelessly to create additional beds for the influx of COVID-19 patients. (Dania Maxwell / Los Angeles Times/TNS)
‘Triage officers’ would decide who gets care and who doesn’t if Covid-19 cripples LA County hospitals
LOS ANGELES – Stretched to the breaking point by a deluge of Covid-19 patients, Los Angeles County’s four public hospitals are preparing to take the extraordinary step of rationing care, with a team of “triage officers” set to decide which patients can benefit from continued treatment and which are beyond saving and should be allowed to die.